(BusinessWire)--Cairn Surgical, Inc., an innovative medical technology company striving to make breast cancer surgery more precise, announced today the results of its pivotal trial evaluating its investigational Breast Cancer Locator (BCLTM) System. The study met its primary endpoint and reported a lower positive margin rate (PMR) across all cancer types when compared to conventional wire localization (WL). Results were presented at the annual meeting of the American Society of Breast Surgeons (ASBrS) currently underway in Seattle.